Page 156 - 2019_10 resto del Mondo_web

L. Patrussi et al.
5. Finetti F, Savino MT, Baldari CT. Positive
and negative regulation of antigen receptor signaling by the Shc family of protein adapters. Immunol Rev. 2009;232(1):115– 134.
6. Capitani N, Lucherini OM, Sozzi E, et al. Impaired expression of p66Shc, a novel reg- ulator of B-cell survival, in chronic lympho- cytic leukemia. Blood. 2010;115(18):3726– 3736.
7. Patrussi L, Capitani N, Cattaneo F, et al. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes. Oncogene. 2018;37(11):1534–1550.
8. Capitani N, Patrussi L, Trentin L, et al. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood. 2012;120(22):4391–4399.
9. Patrussi L, Capitani N, Cannizzaro E, et al. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. Cell Death Dis. 2014;5(2):e1068.
10. Cattaneo F, Patrussi L, Capitani N, et al. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. Oncotarget. 2016;7(35): 57086–57098.
11. Patrussi L, Capitani N, Martini V, et al. Enhanced chemokine receptor recycling and impaired S1P1 expression promote leukemic cell infiltration of lymph nodes in chronic lymphocytic leukemia. Cancer Res. 2015;75 (19):4153–4163.
12. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99(10):6955–6960.
13. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 trans- genic mouse model of CLL by blocking anti- gen-dependent B-cell receptor signaling. Blood. 2010;116(23):4894–4905.
14. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999;402(6759):309–313.
15. Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transforma- tion. Leuk Res. 1999;23(2):127–36.
16. Patrussi L, Ulivieri C, Lucherini OM, et al. p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. Blood. 2007;110(6):1730–1738.
17. Yan X, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713– 11718.
18. Dono M, Cerruti G, Zupo S. The CD5+ B- cell. Int J Biochem Cell Biol. 2004;36(11): 2105–2111.
19. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
20. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development
tool for human chronic lymphocytic
leukemia. Blood. 2006;108(4):1334–1338. 21. Kreiniz N, Beyar Katz O, Polliack A, Tadmor T. The clinical spectrum of hepatic manifes- tations in chronic lymphocytic leukemia. clin lymphoma myeloma leuk. 2017;17(12):
863-869.
22. Carmier D, Dartigeas C, Mankikian J, et al.
Serious bronchopulmonary involvement due to chronic lymphocytic leukaemia. Eur Respir Rev. 2013;22(129):416–419.
23. Pacini S, Pellegrini M, Migliaccio E, et al. p66SHC promotes apoptosis and antago- nizes mitogenic signaling in T cells. Mol Cell Biol. 2004;24(4):1747–1757.
24. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 inte- grin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99(8):2977–2984.
25. Trentin L, Cabrelle A, Facco M, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non- Hodgkin lymphomas. Blood. 2004;104(2): 502–508.
26. Burger JA, Burger M, Kipps TJ. Chronic lym- phocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone mar- row stromal cells. Blood. 1999;94(11):3658– 3667.
27. López-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lym- phocytic leukemia and non-Hodgkin lym- phomas with widespread nodular dissemi- nation. J Leukoc Biol. 2004;76(2):462–471.
28. Cyster JG. Chemokines, sphingosine-1- phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127–159.
29. Akram IG, Georges R, Hielscher T, Adwan H, Berger MR. The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumor Biol. 2016;37(2):2461– 2471.
30. Bigildeev AE, Shipounova IN, Svinareva DA, Drize NJ. Leukemia cells invading the liver express liver chemokine receptors and pos- sess characteristics of leukemia stem cells in mice with MPD-like myeloid leukemia. Exp Hematol. 2011;39(2):187–194.
31. Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 pro- motes the development of colorectal cancer liver metastasis. Hepatology. 2013;57(2): 829–839.
32. Rose CE, Sung S-SJ, Fu SM. Significant involvement of CCL2 (MCP-1) in inflamma- tory disorders of the lung. Microcirculation. 2003;10(3–4):273–288.
33. Jeyanathan M, Afkhami S, Khera A, et al. CXCR3 signaling is required for restricted homing of parenteral tuberculosis vaccine– induced T cells to both the lung parenchyma and airway. J Immunol. 2017;199(7):2555– 2569.
34. Shetty S, Bruns T, Weston CJ, et al. Recruitment mechanisms of primary and malignant B cells to the human liver. Hepatology. 2012;56(4):1521–1531.
35. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive
form of chronic lymphocytic leukemia.
Blood. 1999;94(6):1848–1854.
36. Gào X, Schöttker B. Reduction-oxidation
pathways involved in cancer development: a systematic review of literature reviews. Oncotarget. 2017;8(31):51888–51906.
37. Pozzo F, Dal Bo M, Peragine N, et al. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro func- tional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. J Hematol Oncol. 2013;6:83.
38. Allday MJ, Sinclair A, Parker G, Crawford DH, Farrell PJ. Epstein-Barr virus efficiently immortalizes human B cells without neu- tralizing the function of p53. EMBO J. 1995;14(7):1382–1391.
39. Zurli V, Wimmer G, Cattaneo F, et al. Ectopic ILT3 controls BCR-dependent acti- vation of Akt in B-cell chronic lymphocytic leukemia. Blood. 2017;130(18):2006–2017.
40. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its cor- relation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10(3):456– 459.
41. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxy- gen species. Proc Natl Acad Sci U S A. 2003;100(25):15035–15040.
42. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147(3): 577–594.e1.
43. Belchamber KBR, Donnelly LE. Macrophage dysfunction in respiratory disease. Results Probl Cell Differ. 2017;62:299–313.
44. Trentin L, Agostini C, Facco M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest. 1999;104(1):115–121.
45. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem. 2002;277(25):22370–22376.
46. Pezzicoli A, Ulivieri C, Capitani N, Ventura A, Pelicci P, Baldari CT. Expression in T-cells of the proapoptotic protein p66SHC is con- trolled by promoter demethylation. Biochem Biophys Res Commun. 2006;349 (1):322–328.
47. Chen S-S, Raval A, Johnson AJ, et al. Epigenetic changes during disease progres- sion in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(32):13433–13438.
48. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609–1613.
49. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in nor- mal and malignant cells. Eur J Haematol. 2015;94(3):193–205.
50. Eichhorst B, Fink A-M, Bahlo J, et al. First- line chemoimmunotherapy with ben- damustine and rituximab versus fludara- bine, cyclophosphamide, and rituximab in patients with advanced chronic lympho- cytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-infe- riority trial. Lancet Oncol. 2016;17(7):928– 942.
2052
haematologica | 2019; 104(10)